Precigen (PGEN) Net Income towards Common Stockholders (2012 - 2026)
Precigen (PGEN) reported Net Income towards Common Stockholders of -$7.9 million for Q1 2026, up 85.36% year-over-year from -$4.3 million in Q1 2025, and up 66.26% quarter-over-quarter from -$23.5 million in Q4 2025.
Precigen (PGEN) Net Income towards Common Stockholders (2012 - 2026) Analysis & Trends
Precigen (PGEN) has 14 years of Net Income towards Common Stockholders data on file, last reported at -$7.9 million in Q1 2026.
- Net Income towards Common Stockholders for Q1 2026 came in at -$7.9 million, up 85.36% year-over-year; the trailing twelve-month figure through Mar 2026 was -$383.4 million (down 144.76% YoY), and the FY2025 annual result was -$429.6 million, down 240.35% from the prior year.
- Net Income towards Common Stockholders advanced to -$7.9 million in Q1 2026 per PGEN's latest filing, from -$23.5 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at $95.0 million in Q3 2022 and troughed at -$325.3 million in Q3 2025.
- A 4-year average of -$38.0 million and a median of -$23.6 million in 2024 frame the typical range for Net Income towards Common Stockholders.
- The sharpest annual moves came in 2022 and 2025: Net Income towards Common Stockholders surged 2858.29% in 2022, then sank 1256.84% in 2025.
- A 4-year view of Net Income towards Common Stockholders shows it stood at $95.0 million in 2022, then slumped by 120.76% to -$19.7 million in 2024, then slipped by 19.14% to -$23.5 million in 2025, then soared by 66.26% to -$7.9 million in 2026.
- Business Quant data shows PGEN's Net Income towards Common Stockholders at -$7.9 million in Q1 2026, -$23.5 million in Q4 2025, and -$325.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | -3.63 Mn |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -56.48 Mn |
| 10 | Precigen | 1.27 Bn | 1.27 Bn | 20.69 Mn | -7.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7.93 Mn |
| Dec 31, 2025 | -23.50 Mn |
| Sep 30, 2025 | -325.34 Mn |
| Jun 30, 2025 | -26.64 Mn |
| Mar 31, 2025 | -54.15 Mn |
| Dec 31, 2024 | -19.73 Mn |
| Sep 30, 2024 | -23.98 Mn |
| Jun 30, 2024 | -58.79 Mn |
| Mar 31, 2024 | -23.74 Mn |
| Sep 30, 2022 | 95.02 Mn |
| Jun 30, 2022 | 8.42 Mn |
| Mar 31, 2022 | 4.65 Mn |
| Dec 31, 2021 | 1.66 Mn |
| Sep 30, 2021 | -3.45 Mn |
| Jun 30, 2021 | 10.89 Mn |
| Mar 31, 2021 | 4.53 Mn |
| Dec 31, 2020 | -1.31 Mn |
| Sep 30, 2020 | -1.97 Mn |
| Jun 30, 2020 | -27.65 Mn |
| Mar 31, 2020 | -35.15 Mn |